I believe an option for an ICI will be part of the
Post# of 155263
Max Lataillade wrote on LinkedIn:
Quote:
... CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!

